Cargando…

Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients

BACKGROUND: Pazopanib was recommended as first-line treatment option for Metastatic renal cell carcinoma (mRCC), while evidence from strictly selected patients has poor external validity and clinical characteristics are complex in real-world clinical practice. This study aimed to illustrate the surv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anwaier, Aihetaimujiang, Chen, Jianhui, Zhou, Hongfeng, Zhao, Xinxin, Zheng, Song, Li, Xiaofan, Qu, Yuanyuan, Shi, Guohai, Zhang, Hailiang, Wu, Jin, Ye, Dingwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177258/ https://www.ncbi.nlm.nih.gov/pubmed/35693709 http://dx.doi.org/10.21037/tau-22-312

Ejemplares similares

Deciphering the role of miR-187-3p/LRFN1 axis in modulating progression, aerobic glycolysis and immune microenvironment of clear cell renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2022)

Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data
por: Tian, Xi, et al.
Publicado: (2020)

Adenylate cyclase‐activating polypeptide 1 gene methylation predicts prognosis and the immune microenvironment of bladder cancer
por: Xu, Wenhao, et al.
Publicado: (2021)

m(6)A Regulator-Mediated Methylation Modification Model Predicts Prognosis, Tumor Microenvironment Characterizations and Response to Immunotherapies of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

A novel amino acid metabolism-related gene risk signature for predicting prognosis in clear cell renal cell carcinoma
por: Su, Jiaqi, et al.
Publicado: (2022)

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
por: Bayoğlu, İbrahim Vedat, et al.
Publicado: (2023)

Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment
por: Xu, Wenhao, et al.
Publicado: (2021)

Multi-omics profiles refine L-dopa decarboxylase (DDC) as a reliable biomarker for prognosis and immune microenvironment of clear cell renal cell carcinoma
por: Chang, Kun, et al.
Publicado: (2022)

Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021)

Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Multi-omics reveals novel prognostic implication of SRC protein expression in bladder cancer and its correlation with immunotherapy response
por: Xu, Wenhao, et al.
Publicado: (2021)

Integrative 5-Methylcytosine Modification Immunologically Reprograms Tumor Microenvironment Characterizations and Phenotypes of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer
por: Xu, Wenhao, et al.
Publicado: (2022)

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma
por: Guida, Annalisa, et al.
Publicado: (2020)

Fatty Acid Synthase Correlates With Prognosis-Related Abdominal Adipose Distribution and Metabolic Disorders of Clear Cell Renal Cell Carcinoma
por: Xu, Wenhao, et al.
Publicado: (2021)

Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2022)

Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2022)

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
por: Chen, Jianhui, et al.
Publicado: (2021)

Special issue “The advance of solid tumor research in China”: Multi‐omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response
por: Tian, Xi, et al.
Publicado: (2022)

Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics
por: Ye, Shiqi, et al.
Publicado: (2023)

Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib
por: Lu, Xiaolin, et al.
Publicado: (2016)

Exploration of IMDC model in patients with metastatic renal cell carcinoma using targeted agents: a meta-analysis
por: Jiang, Guiya, et al.
Publicado: (2020)

Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
por: Xu, Wenhao, et al.
Publicado: (2023)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017)

Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
por: Gu, Weijie, et al.
Publicado: (2017)

Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2022)

Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma
por: Wu, Junlong, et al.
Publicado: (2019)

Protumorigenic Role of Elevated Levels of DNA Polymerase Epsilon Predicts an Immune-Suppressive Microenvironment in Clear Cell Renal Cell Carcinoma
por: Wu, Xiaohui, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials
por: Manneh, Ray, et al.
Publicado: (2022)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
por: Attia, Steven, et al.
Publicado: (2015)

The Successful Treatment of Metastatic Extraosseous Ewing Sarcoma with Pazopanib
por: Mori, Yoshinori, et al.
Publicado: (2018)

Pazopanib in rare histologies of metastatic soft tissue sarcoma
por: Kataria, Babita, et al.
Publicado: (2021)

Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi‑institutional retrospective study
por: Kato, Renpei, et al.
Publicado: (2023)

Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival
por: Cao, Dalong, et al.
Publicado: (2019)

Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
por: Cecere, Sabrina C., et al.
Publicado: (2016)

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
por: Koutsoukos, Konstantinos, et al.
Publicado: (2017)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9lotd2em7idpi18ejlbb39ut1u